Invention Grant
US09587281B2 Cereblon isoforms and their use as biomarkers for therapeutic treatment
有权
Cereblon同种型及其用作治疗性治疗的生物标志物
- Patent Title: Cereblon isoforms and their use as biomarkers for therapeutic treatment
- Patent Title (中): Cereblon同种型及其用作治疗性治疗的生物标志物
-
Application No.: US14621298Application Date: 2015-02-12
-
Publication No.: US09587281B2Publication Date: 2017-03-07
- Inventor: Anjan Thakurta , Anita Gandhi , Michelle F. Waldman , Rajesh Chopra , Michael Amatangelo , Chad Bjorklund
- Applicant: Celgene Corporation
- Applicant Address: US NJ Summit
- Assignee: CELGENE CORPORATION
- Current Assignee: CELGENE CORPORATION
- Current Assignee Address: US NJ Summit
- Agency: Jones Day
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/68 ; G01N33/574 ; A61K31/454 ; A61K31/517 ; C07K14/47 ; A61K31/5377
Abstract:
Provided herein are cereblon isoforms and methods of their use as biomarkers for treating a disease, disorder, or condition with a treatment compound, e.g., thalidomide, lenalidomide, pomalidomide, 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-dione, or (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.
Public/Granted literature
- US20150152511A1 CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT Public/Granted day:2015-06-04
Information query
